(Q35132057)

6 August 2017

1 reference

title

Costs and effectiveness--the impact of economic studies on TB control (English)

1 reference

6 August 2017

Floyd K

1

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

83

1 reference

6 August 2017

1-3

1 reference

6 August 2017

187-200

1 reference

How do countries regulate the health sector? Evidence from Tanzania and Zimbabwe

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Community-based tuberculin screening in Montreal: a cost-outcome description

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The economic impact of tuberculosis in hospitals in New York City: a preliminary analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Health-care expenditures for tuberculosis in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Resources required for global tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Medical-resource use for suspected tuberculosis in a New York City hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Costs associated with tuberculosis control programs at hospitals caring for children

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The costs of healthcare worker respiratory protection and fit-testing programs

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Managing exposure to tuberculosis in the PACU: CDC guidelines and cost analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The impact of HIV on resource utilization by patients with tuberculosis in a tertiary referral hospital, Nairobi, Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Does a cheaper mask save money? The cost of implementing a respiratory personal protective equipment program

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The cost of caring for patients with tuberculosis: planning for a disease on the rise

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Reducing tuberculosis detection costs.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Resource implications of patients with multidrug resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Costs of tuberculosis for households and health care providers in Dar es Salaam, Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost savings from alternative treatments for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

An effectiveness and cost analysis of presumptive treatment for Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

[Economic and social impact of the National Tuberculosis Control Program (NTCP) on the Cuban population]

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Epidemiological model and cost-effectiveness analysis of tuberculosis treatment programmes in Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost-effectiveness analysis of three short-course anti-tuberculosis programmes compared with a standard regimen in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Relative value and cost-effectiveness of culture and special stains in fine needle aspirates of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost effectiveness analysis of school based Mantoux screening for TB infection

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

[Cost-benefit analysis of the active screening of pulmonary tuberculosis in a recluse population entering prison]

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Tuberculosis control strategies: the cost of particulate respirators

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

A risk/cost analysis of alternative screening intervals for occupational tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

A cost-benefit analysis of BCG revaccination in the Czech Republic

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Self-assessment of tuberculin skin test reactions by New York City firefighters: reliability and cost-effectiveness in an occupational health care setting.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Annual tuberculin skin testing of employees at a university hospital: a cost-benefit analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Economic evaluation of universal BCG vaccination of Japanese infants

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Costs and benefits of improving tuberculosis control: the case of Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Tuberculin screening: cost-effectiveness analysis of various testing schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Are routine chest X-rays for students entering university worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1472-9792%2802%2900077-X

7 January 2021

10.1016/S1472-9792(02)00077-X

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12758211